SANTA MONICA, Calif., Sept. 20, 2014 /PRNewswire-USNewswire/ -- Three Northern California newspapers have endorsed Proposition 45, comparing it to California's landmark insurance reform initiative Proposition 103 that has saved drivers tens of billions of dollars over the last 25 years and ensured some of the lowest auto insurance rates in the nation.
"Proposition 45 gives voters the opportunity to accomplish the same goal for health insurance, as 35 other states already do. Voters should approve it," wrote the San Jose Mercury-News, the Contra Costa Times and the Oakland Tribune.
Read the editorial: http://www.mercurynews.com/opinion/ci_26434287
Proposition 45 would require health insurance companies to publicly justify their rates and allow the state insurance commissioner to reject rate hikes deemed excessive. The same rules for auto insurance in California have saved drivers $102 billion since 1988. Currently state insurance regulators can review rate hikes, but cannot reject them if they are found to be unreasonable. U.S. Senator Dianne Feinstein is the co-chair of the Prop 45 campaign, which is backed by Consumer Watchdog, the California Nurses Association, and a broad coalition of consumer, labor, low-income, senior and healthcare organizations and providers.
"It's always instructive to see who's backing and opposing propositions. Health insurance companies expect to spend more than $50 million to defeat Prop. 45," the newspapers said. "Their lobbying thwarted three tries in the Legislature to pass rate regulation."
The newspapers put to rest arguments by opponents of rate regulation that the initiative is incompatible with the Affordable Care Act or will cause delays for Covered California, the state's health exchange.
"The Affordable Care Act anticipates that states will have rate regulation. In several states, including Connecticut, New York, Maryland and Oregon, the rules are similar to Prop. 45. They provide compelling evidence that this regulation discourages insurance companies from seeking the kinds of outrageous increases California has seen," the newspapers said. "Allowing public intervenors to challenge rates provides greater transparency to the process and allows the insurance commissioner to get feedback from a wide range of voices."
The editorial concluded: "Prop. 103 in California and health insurance regulations in two thirds of other states show Proposition 45 will work. Voters should approve it."
For more about Proposition 45 visit: www.yeson45.org
SOURCE Consumer Watchdog Campaign
MONT-TREMBLANT, Quebec--(BUSINESS WIRE)-- FibroGen, Inc. (FibroGen) announced today the presentation of the full data set from a clinical study of patients with idiopathic pulmonary fibrosis (IPF) treated for 48 weeks with the investigational drug FG-3019. In the study, lung fibrosis, as measured by quantitative high resolution computed tomography (HRCT), was reduced in a substantial portion of patients who received FG-3019. FG-3019 is a monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a central mediator of fibrotic disease. The data are being presented in oral and poster presentations at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF).
The study enrolled patients with a wide range of IPF severity to assess safety and efficacy of FG-3019 across a broad spectrum of the disease. While other recent clinical trials in IPF have assessed efficacy in terms of changes in pulmonary function, this Phase 2 open-label study measured efficacy by changes in both pulmonary function and pulmonary fibrosis. Patients in two cohorts received intravenous doses of FG-3019 of either 15 mg/kg or 30 mg/kg every three weeks for 45 weeks. The ICLAF presentation provides an updated analysis of efficacy data from all patients treated in the study. Seventy-four (74) patients completed 24 weeks, and 66 of these patients completed 48 weeks of treatment and assessment of changes in pulmonary function and pulmonary fibrosis.
After 24 weeks of treatment, 17 of the 74 patients (23%) had improved fibrosis as measured by quantitative HRCT, and after 48 weeks of treatment, 16 of the 66 patients (24%) had improved fibrosis as measured by quantitative HRCT. FibroGen believes that this is the first trial to demonstrate improved fibrosis in IPF. HRCT is an accurate and reproducible computer-based method to measure fibrotic changes in lung tissue. Recent peer-reviewed publications based on similar quantitative HRCT methods have identified an association between worsening pulmonary fibrosis and mortality in IPF.1 Studies published to date indicate that in untreated IPF patients fibrosis is at best stable but typically worsens over time.
Changes in fibrosis correlated with changes in forced vital capacity, or FVC, at 24 weeks (p=0.0001, r= -0.520) and at 48 weeks (p=0.0001, r= -0.591). On average, patients with improved or stable fibrosis also had improved pulmonary function at week 24 with FVC change of +0.03 liters compared to -0.15 liters for patients with worsening fibrosis (p=0.0001), and at week 48 with FVC change of +0.04 liters compared to -0.23 liters for patients with worsening fibrosis (p=0.0001), indicating improvement in lung function with improvement in lung fibrosis.
The first dose-cohort enrolled patients with a wide range of disease severity: mild to severe (FVC % predicted 45-85%). In the second dose-cohort, enrollment criteria were revised to mild to moderate (FVC % predicted ≥55%) as most patients with severe disease in cohort 1 dropped out of the trial prior to completion. While an analysis of all patients who completed one year of treatment (N=66) showed a mean FVC change of -0.14 liters, mean FVC change for mild to moderate patients at one year (N=60) was -0.11 liters.
Consistent with previously reported interim results, FG-3019 was well tolerated in treated patients. All patients experienced at least one adverse event. There were 38 SAEs in 24 patients, none of which was considered related to study treatment. Adverse events observed have been consistent with those typically observed in this patient population.
Based on these encouraging data, FibroGen is conducting a randomized placebo controlled Phase 2 trial in IPF which is currently enrolling in the US and will soon be expanded to sites outside of the US.
1. Maldonado et al. Eur Resp J 2014; Oda et al. Respiratory Research 2014.
Poster and Oral Presentation Information
Title: Safety and Efficacy of Anti-CTGF Monoclonal Antibody FG-3019 for Treatment of Idiopathic Pulmonary Fibrosis (IPF): Combined Results for Two Cohorts Treated for One YearPoster: September 20, 2014, 3:00pm ETOral Presentation: September 23, 2014, 2:15pm ET
About Idiopathic Pulmonary Fibrosis (IPF)
IPF is a lung disease characterized by a progressive scarring of the lungs that diminishes functional lung volume and hinders oxygen uptake. The cause of IPF is not known, and approximately two-thirds of IPF patients die within five years after diagnosis.
FG-3019 is an investigational therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. FibroGen is currently conducting clinical studies of FG-3019 in idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FG-3019 has been well tolerated, with no apparent safety signals, in more than ten clinical studies and more than 340 treated patients to date.
FibroGen is a privately-held biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of fibrosis, anemia, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia. FibroGen is also currently pursuing the use of proprietary recombinant human type III collagens in synthetic corneas for treatment of corneal blindness. For more information please visit: www.fibrogen.com.
Greg Mann, 415-978-1433
Source: FibroGen, Inc.
DES MOINES, Iowa (PRWEB) September 20, 2014
In keeping with Social Media Week's goal of providing the best information, ideas and inspiration to help people achieve in a hyper-connected world, mygooi said it will be posting to its followers highlights from the 11 cities holding conferences to mark the international event. This will be centered on mygooi's facebook page.
"We'll be watching the conferences, where speakers will share their insights and the latest trends and information with the world," mygooi said, noting that social media represents one of the biggest changes ever in how people communicate. "As this is social media week, it felt right to use our social media tools to distribute some of this valuable content," mygooi said.
Social Media Week (http://socialmediaweek.org/) has organized conferences in Berlin, Chicago, Johannesburg, London, Los Angeles, Miami, Mumbai, Rome, Rotterdam, Sao Paulo and Sydney. These will run from Sept. 22 through 26 and feature presentations on social media trends and the ways companies and individuals can use them.
mygooi™ is an energetic brand platform that is digital, creative, disruptive and global. Its portfolio of emerging products sizzle with IC/DC (Innovation and Creativity/Disruption and Community). mygooi's utility and purpose are to bring people together with innovative digital products. Based in Des Moines, Iowa; Stockholm, Sweden; and Chennai, India, mygooi lives where the sun always shines and has as its mission to Go Where The Life Is.™
See mygooi updates and watch gooination grow on Facebook at
Visit our website and download apps at http://www.mygooi.com.
Jon Buscall, CMO
+46768637285 / jonb(at)mygooi(dot)com
312-315-0707 / Markp(at)mygooi(dot)com
847-651-1445 / Richardg(at)mygooi(dot)com
Read the full story at http://www.prweb.com/releases/2014/09/prweb12187021.htm
Pittsburgh, PA (PRWEB) September 20, 2014
"I was outdoors swinging on my swing, and I thought that this could be turned into a great form of exercise that was fun and effective," said an inventor from Johnston, S.C. "This inspired me to develop a piece of work-out equipment based on a swing."
He developed the ALL IN ONE WORKOUT CHAIR to offer an effective workout. The equipment increases strength and circulation. The device enables the user to perform a variety of upper- and lower-body, as well as abdominal exercises. It is designed to be fun and exciting. The unit promotes regular workouts. Also, it helps the individual lose weight and feel good.
The original design was submitted to the Columbia office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 13-CBA-1776, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com - https://www.youtube.com/user/inventhelp
New York City, NY (PRWEB) September 21, 2014
7 Speed Reading™ salutes the efforts of the Nashville Public Library and 23 other libraries for modernizing and strengthening a library's purpose for learning with the creation of learning labs that appeal to the interests and hobbies of young people.
Speed reading software developer eReflect finds these initiatives to create learning labs for teens a long-overdue operation. Teens across the globe need library resources that match their use of new media. Often, however, outdated curriculum and learning models don't engage students because they don't appeal to their predilections, needs, and goals.
Libraries in Nashville, Chicago, and Minnesota have already opened up their learning labs, creating spaces in which teens are welcome to express their creativity and apply their critical thinking skills, as well as "geek out" to their heart's content.
The idea behind these learning labs in libraries is to promote active learning for young people, and steer them away from outdated learning methodologies that don't serve them any more. Students that can access these learning labs will have state of the art technology at their fingertips, things like 3D printers, recording booths, and other high-tech equipment and resources to bring their ideas into life.
eReflect congratulates the libraries that took up the challenge of modernization, and which have created these learning labs for students.
As the speed reading software designer confirms, these labs were created through grants by the Institute of Museum and Library Services and the MacArthur Foundation. eReflect considers this to be a commendable initiative that could inspire more communities and libraries across the world to develop their own learning labs and help young, talented teens discover and utilize their skills and abilities to the fullest.
Using new media and technologies to drive learning and education is an obvious solution for education in the 21st century, notes eReflect. Several speed reading software reviews of 7 Speed Reading™ show that tech-based learning is an effective approach to knowledge acquisition. The lack of resources and funding is often the main reason why the majority of educational institutions cannot offer their students what these learning labs are offering: a chance to actively learn through the application of the HOMAGO principle (hanging out, messing around and geeking out). eReflect encourages more libraries to adopt this approach, and encourages teens to provide commentary to help those libraries shape the spaces they need to reach their full potential.
For more information about the benefits of using 7 Speed Reading, please visit the official website at http://www.7speedreading.com.
About 7 Speed Reading™
7 Speed Reading is the only modern speed reading software that uses the latest technology to produce superior results.
The software provides its users with a new way to master speed reading that guarantees three times the reading speed along with improved memory and comprehension.
The software is poised as the most comprehensive speed reading system anywhere. It contains seven learning strategies, fifteen software activities, video training, advanced tracking capabilities and many more exciting features.
Read the full story at http://www.prweb.com/releases/2014/09/prweb12169037.htm
More Press ReleasesView Older Stories
UnderMyWear is Now Offering a Wide Range of Chantelle Bras in UK at Affordable Rates
/C O R R E C T I O N -- ART 3/
CITGO Commemorates Ninth Anniversary Of Hurricane Rita; Leads Local Volunteers In Effort To Restore Holly Beach, Louisiana
BIO Welcomes Navy, USDA, DOE Investment in Advanced Biofuels
NASA Launches New Citizen Science Website; Opens Challenge to Participate in Future Mars Missions
InventHelp® Client Develops Customizable Web-Cam Accessory (BTM-2072)
Unity Technologies and Oculus Expand Strategic Partnership
BPH Must Be Treated with Dr. Allen's Device in the First Place But Not with The Gold Standard TURP or Medications as States in the Recent Article, States Fine Treatment
Alcohol Justice Says Roger Goodell and Anheuser-Busch InBev Blame Personal Conduct, Ignore Alcohol Policies and Sponsorship
Storage Space Saver Invented by InventHelp® Client (BTM-2056)
William Lyon Homes' Sales Event Offers Special Deals on Select Homes
USHCC Announces Featured Speakers at 2014 National Convention
Giant Food Alerts Customers To Voluntary Recall Of M&M Brand Milk Chocolate Theater Box
Giant Food Alerts Customers To Voluntary Recall Of Nature's Promise Organic Campfire Trail Mix
Extra Capacity Trash Container Invented by Two InventHelp® Clients (BTM-2045)
Paradise Events Now Offers Consultation for Corporate Events Without Any Charges
Entry deadline is 10 October for international photonics Prism Awards
David Straiton Teases the Upcoming Season 3 of Netflix's Hemlock Grove on Maria Menounos' Online Network AfterBuzz TV
MakerBot at New York Maker Faire
InventHelp® Client Develops Heavy-Duty Hub Lifter (BTM-1062)
Assumable Mortgages Guide Published Online by Real Estate Company
Stop & Shop Alerts Customers To Voluntary Recall Of Nature's Promise Organic Campfire Trail Mix
Powell-Hughes Group Joins ResortQuest Real Estate's Bethany Beach Office
Patagonia Financial Holdings, American Regional Center Group Partner With My Ceviche
CHANGE TO THE BOARD OF DIRECTORS
CSX and ACTrees Commemorate Star-Spangled 200
InventHelp® Client Develops Heavy-Duty Hub Lifter (BSJ-205)
Boeing, Ethiopian Airlines Announce Order for 20 737 MAX 8s
Hundreds Rode In Cycle For Survival's Times Square Takeover To Launch 2015 Registration
Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today
Two InventHelp® Clients Develop Traffic-Direction Sign (BSJ-201)
No Medical Exam Life Insurance Provides Financial Protection for Families
Inventor® Develops Enhanced Snowboard (BSJ-162)
Novel Exerciser for Back, Lower Body Invented by InventHelp Client (LFY-846)
Getting 'Wellthy': Mediaplanet's "Work-Life Wellness" campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians
New Responsive Website Launched by DiamondStuds.com The Premier Online Diamond Earrings Retailer
InventHelp Inventor Designs a More Reliable, Longer-Lasting HVAC Filter (LFY-700)
Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month
East Bay SPCA Proudly Announces AAHA Accreditation
Monitor Babies in Car Seats Easily with EYE SEE YOU - Designed by InventHelp Client (LCC-246)
2015 Honeymoon Tour Tickets: Ariana Grande Concert Tickets Now On Sale Today
Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today
Inventor and InventHelp Client Designs Convenient Pouring Accessory for 2 Liter Bottles (LCC-241)
Ariana Grande Tickets in New York, Philadelphia, Seattle, Orlando, Fairfax, San Jose and Detroit On Sale Today at TicketProcess.com
By Popular Demand Third Show Added for Dave Chappelle at DPAC, Durham Performing Arts Center, in Durham, NC November 7-9, 2014
Restaurant Owners Get A $20 Savings On 2014 EzPaycheck Software As Additional Incentive
Annual City-Wide Food Drive Shoots for a World Record Today
Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today
HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio
Best Web Hosting for Wiki Websites from ThreeHosts.com